Abstract

Lung cancer is the second most common cancer type in men and women worldwide, and the most frequent type of cancer that causes death in both sexes. Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that has extracellular ligand binding and intracellular tyrosine kinase segments. Agents such as Erlotinib, Gefitinib, Afatinib, Lapatinib inhibit the activation of the intracellular tyrosine kinase domain of EGFR. These agents are usually well tolerated. Skin rash is the most common skin toxicity during treatment. Alopecia related to erlotinib therapy is a condition that can be seen.. Elderly and female patients may be confronted with long-term treatment. It can be seen as a cicatricial and non-cicatricial alopecia. In this study, we tried to present our case that developing alopecia related to the use of erlotinib.